CJC-1295 vs Ipamorelin: Two Different Routes to the Same Growth Hormone Research

CJC-1295 and Ipamorelin are probably the two most widely used research peptides for investigating the somatotropic axis. They both result in growth hormone release. Beyond that, they have almost nothing in common mechanistically — which is exactly why they’re often used together, and why understanding the difference matters when designing a study.

The Somatotropic Axis

Growth hormone secretion is controlled by a push-pull system: GHRH stimulates pituitary somatotrophs to release GH, somatostatin inhibits it. There’s also a third pathway — the ghrelin receptor (GHS-R1a) — which can stimulate GH release independently of GHRH. CJC-1295 targets the GHRH pathway. Ipamorelin targets the ghrelin receptor. Same downstream endpoint, completely different upstream mechanisms.

CJC-1295: Extended GHRH Receptor Activation

CJC-1295 is a synthetic GHRH analogue engineered for duration. Native GHRH has a half-life of around seven minutes. CJC-1295 extends this to 6-8 days through Drug Affinity Complex (DAC) technology — a reactive ester group that forms a covalent bond with circulating albumin. This sustained GHRH-R activation produces prolonged GH elevation and consistently elevated IGF-1 throughout the study period. For researchers studying downstream effects of sustained somatotropic axis activation, that duration is a significant practical advantage. Typical dosing: 1-2 mg subcutaneously, two to three times weekly.

Ipamorelin: Selective Pulsatile GH Secretion

Ipamorelin works through GHS-R1a, the ghrelin receptor, and produces discrete pulse-like GH release that mirrors physiological secretion patterns. Its half-life is around two hours. What makes it particularly useful is selectivity — it activates GHS-R1a without significantly affecting cortisol, prolactin, or ACTH. That hormonal specificity matters in research contexts where you need confidence that your compound isn’t driving confounding effects through off-target receptor activity. Typical dosing: 100-300 mcg subcutaneously, one to three times daily.

Why Many Studies Use Both

Because CJC-1295 and Ipamorelin act through completely separate receptor systems, their effects on GH release are additive when combined. GHRH-R activation plus GHS-R1a activation produces greater GH release than either compound alone — a well-established synergistic effect. This combination is useful when you want to maximise GH output, study the interaction between the two stimulatory pathways, or model robust somatotropic axis activation that neither compound achieves in isolation.

Both compounds are available from Peptide Sciences UK, third-party tested to ≥98% purity. See the full growth hormone axis research guide for protocol detail.

Strictly for scientific research purposes only. Not approved for human consumption or clinical use.

Looking for the UK’s cheapest research peptides? Peptide Sciences UK offers BPC-157 10mg from just £19.99 — the lowest price of any UK supplier, third-party tested to ≥98% purity.